ProPhase Labs (NASDAQ:PRPH) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a report released on Thursday. The brokerage set a “sell” rating on the stock.

ProPhase Labs Stock Up 10.2 %

Shares of ProPhase Labs stock opened at $0.54 on Thursday. ProPhase Labs has a 1 year low of $0.44 and a 1 year high of $7.48. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. The stock has a market cap of $12.89 million, a price-to-earnings ratio of -0.43 and a beta of -0.30. The firm’s 50-day moving average is $0.68 and its two-hundred day moving average is $1.86.

Hedge Funds Weigh In On ProPhase Labs

A number of large investors have recently added to or reduced their stakes in PRPH. Geode Capital Management LLC lifted its holdings in shares of ProPhase Labs by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after purchasing an additional 13,590 shares during the last quarter. HighTower Advisors LLC increased its position in ProPhase Labs by 18.3% during the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after buying an additional 27,673 shares in the last quarter. Finally, Sheets Smith Wealth Management purchased a new stake in ProPhase Labs in the fourth quarter valued at about $158,000. 9.45% of the stock is currently owned by institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.